Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01031862 · ClinicalTrials.gov registry record · NA

BMS Reverse Cholesterol Transport (RCT) Study

A NA study of Healthy, sponsored by University of Pennsylvania.

Completed
Registry status
NA
Development phase
12
Enrollment target
1
Study location

NCT01031862: Completed NA study of Healthy, sponsored by University of Pennsylvania.

NCT01031862 is a NA study of Healthy that has completed, run by University of Pennsylvania. The registered enrollment target is 12 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01031862, a NA study of Healthy, has completed, sponsored by University of Pennsylvania.

COMPLETED
Registry status
NA
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to investigate the use of radiolabeled particulate cholesterol administered intravenously in association with albumin, as a method to study reverse cholesterol transport (RCT) in humans by analyzing changes in the tracer activity in total plasma, lipoproteins and feces.

Conditions Studied

Interventions

  • OTHER 3H-Cholesterol

Study Locations (1)

Pennsylvania

  • University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2009-11
Est. Completion 2010-06
Phase NA

Sponsor

University of Pennsylvania

1,423 total trials

What the Registry Record Tells You About NCT01031862

The ClinicalTrials.gov registry entry for NCT01031862 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which 3H-Cholesterol is the first listed.

NCT01031862 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT01031862 about?

NCT01031862 is a clinical study titled "BMS Reverse Cholesterol Transport (RCT) Study". The purpose of this study is to investigate the use of radiolabeled particulate cholesterol administered intravenously in association with albumin, as a method to study reverse cholesterol transport (RCT) in humans by analyzing changes in the tracer activity in total plasma, lipoproteins and feces.

What is the current status of trial NCT01031862?

This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2009-11. Estimated completion is 2010-06.

What conditions does trial NCT01031862 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT01031862?

The interventions under investigation include: 3H-Cholesterol (OTHER).

Who is sponsoring clinical trial NCT01031862?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01031862 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.